Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01

Company News

Hemostemix (TSXV:HEM; OTCQB:HMTXF) is pleased to provide the following update on its research and development activities. As quoted in the press release: Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and refinements to its manufacturing process, the Company is pleased to announce it has made additional findings …

Hemostemix (TSXV:HEM; OTCQB:HMTXF) is pleased to provide the following update on its research and development activities.

As quoted in the press release:

Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and refinements to its manufacturing process, the Company is pleased to announce it has made additional findings surrounding its overall technology platform and initiation of R&D work on NCP-01, another one of its product pipeline candidates.

As disclosed in its recent press release, the Company has been furthering its research and development (“R&D”) initiatives with a focus on optimizing the manufacturing process of ACP-01, with an underlying focus on continuing to expand the potential of the Company’s technology platform. As previously announced, the Company has a manufacturing agreement in place with Aspire Health Science LLC (“Aspire”) to have access to Aspire’s laboratory and personnel for R&D purposes. Over the past several months, the Company has run a total of thirty-nine (39) research batches which not only resulted in refinements to its manufacturing protocols, which, subject to regulatory approvals, will reduce product manufacturing time by 40% from five to three days, but has also resulted in findings surrounding the expansion of its technology platform to use an allogeneic process and further its research on NCP-01.

Click here to read the full press release.

The Conversation (0)
×